Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 9, Issue 4, Pages 196-197Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2012.36
Keywords
-
Categories
Funding
- NCI NIH HHS [P50 CA058223] Funding Source: Medline
Ask authors/readers for more resources
Recent neoadjuvant studies have examined the effects of adding single or dual agents targeting HER2 to chemotherapy, finding unanimously that dual HER2 targeting markedly improves pathologic response. These findings have significant implications for future trial designs, particularly if the impact on pathologic response is accompanied by improved disease-free survival or overall survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available